The antagonistic activity profile of naloxone in μ-opioid receptor agonist-induced psychological dependence.


Journal

Neuroscience letters
ISSN: 1872-7972
Titre abrégé: Neurosci Lett
Pays: Ireland
ID NLM: 7600130

Informations de publication

Date de publication:
14 09 2020
Historique:
received: 18 05 2020
revised: 11 06 2020
accepted: 15 06 2020
pubmed: 23 6 2020
medline: 14 5 2021
entrez: 23 6 2020
Statut: ppublish

Résumé

Naloxone is a μ-opioid receptor antagonist that has been used to prevent overdose-related respiratory depression and deaths by the illicit use of opioids. Naloxone can also deter the abuse potential of opioids, but little has been reported regarding its antagonistic activity profile against opioid-induced psychological dependence. This study aimed to confirm the antagonistic activity profile of naloxone against several μ-opioid receptor agonists and investigate whether naloxone could affect the psychological dependence induced by widely used μ-opioid receptor agonist, oxycodone. In the Guanosine-5'-o-(3-thio) triphosphate (GTPγS) binding assay, naloxone (30-30,000 nM) inhibited the GTPγS binding induced by oxycodone, hydrocodone, morphine, and fentanyl. It elicited parallel rightward shifts in the concentration-response curves, indicating that naloxone possessed a competitive antagonistic activity profile against these μ-opioid receptor agonists. In the conditioned place preference test, oxycodone (0.01-1 mg/kg, i.v.) produced dose-dependent increases in place preference. The increased place preference induced by oxycodone (1 mg/kg) was significantly attenuated by co-administration of naloxone at a dose of 0.5 mg/kg but not 0.01 mg/kg. Naloxone (0.5 mg/kg, i.v.) also blocked oxycodone (1 mg/kg)-induced dopamine release in nucleus accumbens; however, at a lower dose (0.01 mg/kg), it did not affect the intrinsic dopamine release by oxycodone. These results indicate that the psychological dependence of oxycodone could be antagonized by naloxone, depending on the dose. This characterization might lead to a better understanding of the competitive antagonistic activity profile of naloxone for μ-opioid receptor in the brain.

Identifiants

pubmed: 32569809
pii: S0304-3940(20)30447-X
doi: 10.1016/j.neulet.2020.135177
pii:
doi:

Substances chimiques

Analgesics, Opioid 0
Narcotic Antagonists 0
Receptors, Opioid, mu 0
Naloxone 36B82AMQ7N
Oxycodone CD35PMG570

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135177

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Auteurs

Atsushi Nakamura (A)

Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Kana Yasufuku (K)

Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Shinji Shimada (S)

Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Hiroyuki Aritomi (H)

Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Youko Furue (Y)

Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Hiroki Chiba (H)

Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Mami Muramoto (M)

Research Area for Pharmacological Evaluation, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Kenji Takase (K)

Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Katsumi Koike (K)

Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Tomoko Matsumoto (T)

Research Area for Candidate Selection, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Tomoka Shimada (T)

Research Area for Candidate Selection, Shionogi TechnoAdvance Research Co., Ltd, 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Ryosuke Watari (R)

Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Takanobu Matsuzaki (T)

Laboratory for Drug Discovery and Development, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Toshiyuki Asaki (T)

Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Toshiyuki Kanemasa (T)

Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan.

Masahide Fujita (M)

Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., 1-1, 3-chome, Futaba-cho, Toyonaka, 561-0825, Osaka, Japan. Electronic address: masahide.fujita@shionogi.co.jp.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH